{
    "ticker": "PHVS",
    "name": "PhaseBio Pharmaceuticals, Inc.",
    "description": "PhaseBio Pharmaceuticals, Inc. is a biotechnology company focused on developing innovative therapies for patients with rare and specialty diseases. Founded in 2015 and headquartered in Malvern, Pennsylvania, PhaseBio is dedicated to addressing significant unmet medical needs through its proprietary technology platforms. The company is known for its work in stabilizing biologics and enhancing their delivery, particularly in the areas of cardiology and endocrinology. One of its lead candidates, PB2452, is an investigational treatment designed to reverse the effects of antiplatelet therapy in patients undergoing surgical procedures. The company aims to bring transformative therapies to market that can significantly improve patient outcomes. With a strong emphasis on research and development, PhaseBio is committed to advancing its pipeline of product candidates while also pursuing strategic partnerships to enhance its capabilities and reach within the biopharmaceutical landscape.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Malvern, Pennsylvania, USA",
    "founded": "2015",
    "website": "https://www.phasebio.com",
    "ceo": "Adam B. Gridley",
    "social_media": {
        "twitter": "https://twitter.com/PhaseBio",
        "linkedin": "https://www.linkedin.com/company/phasebio/"
    },
    "investor_relations": "https://investors.phasebio.com",
    "key_executives": [
        {
            "name": "Adam B. Gridley",
            "position": "CEO"
        },
        {
            "name": "Chris P. McEwen",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Therapeutics",
            "products": [
                "PB2452"
            ]
        }
    ],
    "seo": {
        "meta_title": "PhaseBio Pharmaceuticals, Inc. | Innovative Biotech Solutions",
        "meta_description": "Explore PhaseBio Pharmaceuticals, Inc., a biotech leader focused on developing innovative therapies for rare diseases. Learn about our pipeline and mission.",
        "keywords": [
            "PhaseBio",
            "Biotechnology",
            "Pharmaceuticals",
            "Rare Diseases",
            "PB2452"
        ]
    },
    "faq": [
        {
            "question": "What does PhaseBio Pharmaceuticals focus on?",
            "answer": "PhaseBio focuses on developing innovative therapies for patients with rare and specialty diseases."
        },
        {
            "question": "Who is the CEO of PhaseBio Pharmaceuticals?",
            "answer": "Adam B. Gridley is the CEO of PhaseBio Pharmaceuticals, Inc."
        },
        {
            "question": "Where is PhaseBio headquartered?",
            "answer": "PhaseBio is headquartered in Malvern, Pennsylvania, USA."
        },
        {
            "question": "What is PB2452?",
            "answer": "PB2452 is an investigational treatment being developed by PhaseBio to reverse the effects of antiplatelet therapy."
        },
        {
            "question": "When was PhaseBio founded?",
            "answer": "PhaseBio was founded in 2015."
        }
    ],
    "competitors": [
        "AMRN",
        "SRPT",
        "BMRN",
        "ALNY"
    ],
    "related_stocks": [
        "VRTX",
        "REGN",
        "GILD",
        "BMY"
    ]
}